Rise in incidence of cancer across the world, surge in global geriatric population, and supportive reimbursement policies for immune checkpoint inhibitors drive the growth of the global immune checkpoint inhibitors market.
PORTLAND, Ore., Jan. 9, 2023 /PRNewswire/ — Allied Market Research published a report, titled, “Immune Checkpoint Inhibitor Market by Type (PD-1 Inhibitor, PD-L1 Inhibitor, and CTLA4 Inhibitor) and Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Colorectal Cancer and Others): Global Opportunity Analysis and Industry Forecast, 2021-2031″. According to the report, the global immune checkpoint inhibitors industry generated $34.9 billion in 2021, and is anticipated to generate $155.1 billion by 2031, witnessing a CAGR of 16.1% from 2022 to 2031.
Prime determinants of growth
Rise in incidence of cancer across the world, surge in global geriatric population, and supportive reimbursement policies for immune checkpoint inhibitors drive the growth of the global immune checkpoint inhibitors market. On the other hand, high cost of immune checkpoint inhibitors impedes the growth to some extent. However, an increase in the number of pipeline drugs is expected to create lucrative opportunities in the industry.
Download Free Sample Report- https://www.alliedmarketresearch.com/request-sample/3723
- The outbreak of the Covid-19 pandemic had a negative impact on the global immune checkpoint inhibitors market. This is owing to a decline in the number of cancer patient visits in hospitals and clinics for immune checkpoint inhibitor therapy (ICI) which, in turn, gave way to a reduced demand of immune checkpoint inhibitors products.
- However, the market is anticipated to get back on track soon. This is attributed to the increase in the prevalence of cancer and chronic diseases as well as an increase in the demand for novel drug therapies for the treatment of cancer.
The PD-1 inhibitor segment to maintain its leadership status throughout the forecast period
Based on type, the PD-1 inhibitor segment accounted for around three-fourths of the total immune checkpoint inhibitors market share in 2021, and is expected to rule the roost by 2031, owing to the increase in prevalence of various type of cancer along with a rise in geriatric population across the world. The PD-L1 inhibitor segment, on the other hand, would garner the fastest CAGR of 15.6% throughout the forecast period, owing to a rise in the number of PD-L1 drugs in pipeline.
The lung cancer segment to maintain its leadership status throughout the forecast period
Based on application, the lung cancer segment contributed to more than one-third of the total immune checkpoint inhibitors market revenue in 2021, and is projected to lead the trail by 2031. The same segment would also exhibit the fastest CAGR of 17.0% during the forecast period, owing tothe surge in the prevalence of lung cancer of across the world.
For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/3723
North America to maintain its dominance by 2031
Based on region, the market across North America held the major share in 2020, garnering more than three-fifths of the global immune checkpoint inhibitors market and is estimated to maintain its leadership status throughout the forecast period, owing to high expenditure on R&D, presence of major players & their product availability, and well-established healthcare infrastructure in the region. The Asia-Pacific region, however, would manifest the fastest CAGR of 18.4% throughout the forecast period, owing to the improvement in R&D facilities, available disposable income, and rapidly developing economic conditions in the region.
Leading Market Players: –
- AstraZeneca PLC
- Bristol Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline PLC
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Merck KGaA
- BeiGene Ltd.
- Shanghai Jhunsi Biosciences Ltd.
The report provides a detailed analysis of these key players of the global immune checkpoint inhibitors market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Trending Reports in Healthcare Industry-
Upper Limb Prosthetics Market – Global Opportunity Analysis and Industry Forecast, 2020-2030
COPD and Asthma Devices Market – Global Opportunity Analysis and Industry Forecast, 2020–2030
Vascular Disease Devices Market – Global Opportunity Analysis and Industry Forecast, 2020–2030
Oral Cancer Treatment Market – Global Opportunity Analysis and Industry Forecast, 2020–2030
Wearable Injectors Market – Global Opportunity Analysis and Industry Forecast, 2020–2030
Computed Tomography (CT) Market – Global Opportunity Analysis and Industry Forecast, 2020–2030
Empty Capsules Market – Global Opportunity Analysis and Industry Forecast, 2020–2030
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Follow Us on: LinkedIn Twitter
View original content:https://www.prnewswire.co.uk/news-releases/immune-checkpoint-inhibitors-market-predicted-to-reach-usd-155-1-billion-globally-by-2031-at-16-1-cagr-allied-market-research-301716300.html